Artiva Biotherapeutics
ARTV
NASDAQ
IPO2024
about ARTV
Artiva Biotherapeutics is a biopharmaceutical company dedicated to creating cutting-edge treatments for autoimmune disorders through its lead product, an IL-17A/F inhibitor named SKYLCAT, aimed at reducing inflammation and addressing patient needs.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $4.09 | $7.25 | $4.08 | $81.00M | 47.77M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.88 | n/a | n/a | 0% | 0% | 0% |